- Home
- KFS vs GLUE Comparison
KFS vs GLUE Comparison
Compare KFS & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KFS
- GLUE
- Stock Information
- Founded
- KFS 1989
- GLUE 2019
- Country
- KFS United States
- GLUE United States
- Employees
- KFS N/A
- GLUE N/A
- Industry
- KFS Property-Casualty Insurers
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- KFS Finance
- GLUE Health Care
- Exchange
- KFS Nasdaq
- GLUE Nasdaq
- Market Cap
- KFS 417.8M
- GLUE 351.2M
- IPO Year
- KFS 1996
- GLUE 2021
- Fundamental
- Price
- KFS $14.37
- GLUE $4.80
- Analyst Decision
- KFS
- GLUE Buy
- Analyst Count
- KFS 0
- GLUE 2
- Target Price
- KFS N/A
- GLUE $13.50
- AVG Volume (30 Days)
- KFS 69.0K
- GLUE 369.2K
- Earning Date
- KFS 08-07-2025
- GLUE 08-07-2025
- Dividend Yield
- KFS N/A
- GLUE N/A
- EPS Growth
- KFS N/A
- GLUE N/A
- EPS
- KFS N/A
- GLUE 0.29
- Revenue
- KFS $119,287,000.00
- GLUE $177,986,000.00
- Revenue This Year
- KFS N/A
- GLUE $83.76
- Revenue Next Year
- KFS N/A
- GLUE N/A
- P/E Ratio
- KFS N/A
- GLUE $16.32
- Revenue Growth
- KFS 12.05
- GLUE 2990.57
- 52 Week Low
- KFS $7.06
- GLUE $3.50
- 52 Week High
- KFS $16.80
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- KFS 54.71
- GLUE 51.69
- Support Level
- KFS $13.96
- GLUE $4.54
- Resistance Level
- KFS $14.36
- GLUE $4.93
- Average True Range (ATR)
- KFS 0.38
- GLUE 0.21
- MACD
- KFS 0.05
- GLUE 0.06
- Stochastic Oscillator
- KFS 89.60
- GLUE 81.43
About KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The firm generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.